HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
Sample Articles
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
PRODUCTS
CONTACT US
The Medical Letter Mobile Home Page
CURRENT
ISSUE
1612
The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization (see Table...  read more...
More from issue 1612
Coming Soon
Drugs for Asthma
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
Ofatumumab (Kesimpta) for Multiple Sclerosis
An EUA for Baricitinib for COVID-19
An EUA for Casirivimab and Imdevimab - A Monoclonal Antibody Combination for COVID-19
Recommend to Your Library  
Previous Issues
© 2020 The Medical Letter, Inc.